Morgan Stanley updates 3M risk-reward: Maintains Equal-weight, $165 price target

Overview

This report is Morgan Stanley's risk-reward update on 3M Co., prompted by pre-earnings model adjustments to EPS components. The core conclusion is that 3M's risk-reward profile is becoming more balanced after the market consensus organic growth hurdle declined from approximately 4% to 2%-3%; self-help improvements, operating margin expansion, and relative growth improvement in a weak macroeconomic environment support a valuation re-rating, but consumer demand, channel destocking, tariffs, and litigation liabilities continue to limit further upside.

Core views

Morgan Stanley maintains its Equal-weight rating and $165 price target for 3M. The base case assumes low-single-digit organic growth through 2027, strong operating margin expansion from self-help measures in 2026 that is partially offset by tariffs, and a valuation based on approximately 20.0x blended 2027/2028 EPS, adjusted for the present value of after-tax litigation liabilities and the net impact of the SOLV holding. The bull case has a $220 price target, relying on improving consumption, channels shifting from destocking to restocking, approximately 4% organic growth, and an operating margin of approximately 26.5% by 2027. The bear case has a $125 price target, reflecting weak consumption, continued channel destocking, more moderate margin expansion, and an approximately 18x valuation multiple.

Analysis framework

The report applies a scenario-based risk-reward framework, dividing 3M into base, bull, and bear cases, and validating the price target through blended 2027/2028 EPS multiples, the present value of litigation liabilities, the net impact of the SOLV holding, and sum-of-the-parts valuation. It also tracks drivers including organic growth, operating margin, consumer spending, restructuring plans, relative macroeconomic growth, and ownership positioning.

Methodology notes

• Valuation methodP/E multiple valuation

  Blended 2027/2028 EPS multiple

  The base case uses approximately 20.0x blended 2027/2028 EPS, the bull case approximately 23.0x, and the bear case approximately 18.0x, with adjustments for the present value of litigation liabilities and the net impact of the SOLV holding.

• Valuation methodSum-of-the-parts valuation

  SoTP

  The report states that sum-of-the-parts valuation is used to further support the price target methodology and cross-check the multiple-based valuation conclusion.

• Risk-reward frameworkBull/Base/Bear Case

  Three-scenario price targets

  The report provides bull, base, and bear price targets of $220, $165, and $125, respectively, to illustrate the impact of variables such as organic growth, margins, consumer demand, and litigation liabilities on the share price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 3M Co. (MMM.N)

  Covered asset, US equity

  Strengths

  Self-help measures led by new CEO Bill Brown are translating into operating margin expansion; the company is showing improved relative organic growth performance in a weak macroeconomic environment; and the lower consensus growth hurdle reduces the difficulty of delivering results.

  Weaknesses

  Organic growth has lagged nominal GDP for much of the past decade; pressure on consumer spending and channel destocking continue to affect revenue; and litigation liabilities remain a valuation discount factor.

  Comparison

  The base valuation is approximately 20x blended 2027/2028 EPS, representing approximately a 10% discount to the S&P 500; the bull case is approximately 23x, near 2014-2019 levels before PFAS concerns and at a mid-single-digit premium to peers; the bear case is approximately 18x, below the peer average.

  Risks

  Key risks include continued consumer pressure, delayed returns on growth investment, slower margin improvement, tariff impacts, and litigation liabilities such as PFAS exceeding expectations.

Key data

• RatingEqual-weightMorgan Stanley's current stock rating.
• Industry viewAttractiveThe industry view disclosed in the report.
• Price target$165.00Base-case price target.
• Current share price$155.34Closing price on July 9, 2026.
• Implied upsideApproximately 6.2%Calculated from the $165.00 price target relative to the $155.34 share price.
• Bull-case price target$220.00Based on approximately 4% organic growth, approximately 26.5% 2027 operating margin, and approximately 23x blended EPS.
• Bear-case price target$125.00Based on subdued consumer demand, low-to-mid-single-digit organic growth, and approximately 18x blended EPS.
• 2026e EPS8.73Morgan Stanley estimate in the report table.
• 2027e EPS9.39Morgan Stanley estimate in the report table.
• 2028e EPS9.79Morgan Stanley estimate in the report table.
• 2025 operating margin23.4%Key earnings input.
• 2027e operating margin24.9%Key earnings input; the bull case separately cites approximately 26.5%.
• 2026e organic growth2.9%Key earnings input.
• 2027e organic growth2.7%Key earnings input.

Impact & implications

The report's implication for 3M is neutral-leaning: after growth expectations were lowered, the market's delivery requirements for the company have decreased, while self-help measures and margin improvement help sustain valuation; however, the limited upside from the current price to the price target indicates that Morgan Stanley believes the current price already largely reflects management improvement and a multiple re-rating. If organic growth reaccelerates or margin expansion exceeds expectations, there remains room for further valuation upside; conversely, consumer pressure, tariffs, and rising litigation liabilities would weigh on earnings and valuation.

Risks

• Continued pressure on consumer spending weighs on 3M's organic growth outlook.
• Continued channel destocking delays the recovery in end demand and revenue.
• Tariffs offset some of the margin improvement from self-help measures.
• Increased reinvestment to drive future growth may cause margin improvement to fall short of expectations.
• PFAS, US federal and state water-related, personal injury, and EU PFAS-related litigation liabilities may exceed expectations.
• Morgan Stanley has investment banking and financing service relationships with 3M; the report's disclosures remind investors to consider potential conflicts of interest.

What to watch

• EPS revisions and 2026/2027 organic growth guidance before and after the earnings release.
• Consumer spending trends and evidence that channels are shifting from destocking to restocking.
• Whether restructuring, self-help programs, and new product introductions led by new CEO Bill Brown continue to drive operating margin expansion.
• The contribution of self-help measures such as OTIF and new product launches to revenue growth.
• Progress on PFAS and other litigation liabilities and their impact on cash flow.
• The impact of tariffs on costs, margins, and the pace of reinvestment.